Liraglutide: a Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

Overview

Journal Drugs

Specialty Pharmacology

Date 2014 Nov 5

PMID 25367717

Citations 17

Authors

Lesley J Scott

Affiliations

Soon will be listed here.

Abstract

Subcutaneous liraglutide (Victoza(®)), a glucagon-like peptide 1 receptor agonist, is approved for the treatment of adult patients with type 2 diabetes mellitus. Once-daily liraglutide, as monotherapy or add-on therapy to other antidiabetic agents (including basal insulin), was an effective and generally well tolerated treatment in adult patients with type 2 diabetes in several well-designed phase III trials and in the real world clinical practice setting. In addition to improving glycaemic control, liraglutide had beneficial effects on bodyweight, systolic blood pressure and surrogate measures of β-cell function in clinical trials, with these benefits maintained during long-term treatment (≤2 years). Liraglutide has a convenient once-daily administration regimen, a low potential for drug-drug interactions and low propensity to cause hypoglycaemia. Thus, liraglutide continues to be a useful option for the management of type 2 diabetes. This article reviews the therapeutic use of liraglutide in adult patients with type 2 diabetes and summarizes its pharmacological properties.

Citing Articles

Legume-Derived Bioactive Peptides in Type 2 Diabetes: Opportunities and Challenges.

Hu K, Huang H, Li H, Wei Y, Yao C Nutrients. 2023; 15(5).

PMID: 36904097 PMC: 10005352. DOI: 10.3390/nu15051096.

Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.

Silva-Nunes J, Nascimento E, Louro J, Dores J, Laginha T, Goncalves-Ferreira A Metabolites. 2022; 12(11).

PMID: 36422260 PMC: 9694138. DOI: 10.3390/metabo12111121.

A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects.

Zhou R, Guo L, Gao X, Wang Y, Xu W, Zou Y Clin Transl Sci. 2022; 15(10):2458-2467.

PMID: 35871497 PMC: 9579399. DOI: 10.1111/cts.13374.

Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.

Hakim M, Fathi M, Abdulraziq M, Al Shehri M Surg Endosc. 2022; 36(11):8503-8508.

PMID: 35488131 DOI: 10.1007/s00464-022-09294-8.

Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.

Alsafwani D, Alotaibi H, Alzaid J, Alghamdi A, Almakhaita H Cureus. 2022; 14(3):e23554.

PMID: 35371841 PMC: 8958214. DOI: 10.7759/cureus.23554.

References

Hermansen K, Baekdal T, During M, Pietraszek A, Mortensen L, Jorgensen H . Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013; 15(11):1040-8. DOI: 10.1111/dom.12133. View

Nauck M, Friedrich N . Do GLP-1-based therapies increase cancer risk?. Diabetes Care. 2013; 36 Suppl 2:S245-52. PMC: 3920789. DOI: 10.2337/dcS13-2004. View

Kaku K, Rasmussen M, Clauson P, Seino Y . Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010; 12(4):341-7. DOI: 10.1111/j.1463-1326.2009.01194.x. View

Flint A, Kapitza C, Zdravkovic M . The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab. 2013; 15(10):958-62. DOI: 10.1111/dom.12108. View

Singh S, Chang H, Richards T, Weiner J, Clark J, Segal J . Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013; 173(7):534-9. DOI: 10.1001/jamainternmed.2013.2720. View

Heymann A, Maor Y, Goldstein I, Todorova L, Schertz-Sternberg P, Karasik A . Efficacy of liraglutide in a real-life cohort. Diabetes Ther. 2014; 5(1):193-206. PMC: 4065284. DOI: 10.1007/s13300-014-0062-2. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

. Standards of medical care in diabetes--2014. Diabetes Care. 2013; 37 Suppl 1:S14-80. DOI: 10.2337/dc14-S014. View

Garber A, Henry R, Ratner R, Hale P, Chang C, Bode B . Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13(4):348-56. PMC: 3084519. DOI: 10.1111/j.1463-1326.2010.01356.x. View

10.

Buse J, Garber A, Rosenstock J, Schmidt W, Brett J, Videbaek N . Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD).... J Clin Endocrinol Metab. 2011; 96(6):1695-702. DOI: 10.1210/jc.2010-2822. View

11.

Yang L, He Z, Tang X, Liu J . Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2012; 25(2):225-31. DOI: 10.1097/MEG.0b013e32835af154. View

12.

Seino Y, Rasmussen M, Nishida T, Kaku K . Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial. J Diabetes Investig. 2014; 2(4):280-6. PMC: 4014968. DOI: 10.1111/j.2040-1124.2011.00103.x. View

13.

Croom K, McCormack P . Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009; 69(14):1985-2004. DOI: 10.2165/11201060-000000000-00000. View

14.

Egan A, Blind E, Dunder K, de Graeff P, Hummer B, Bourcier T . Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014; 370(9):794-7. DOI: 10.1056/NEJMp1314078. View

15.

Stolar M . Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010; 123(3 Suppl):S3-11. DOI: 10.1016/j.amjmed.2009.12.004. View

16.

Buse J, Rosenstock J, Sesti G, Schmidt W, Montanya E, Brett J . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683):39-47. DOI: 10.1016/S0140-6736(09)60659-0. View

17.

Nauck M, Frid A, Hermansen K, Shah N, Tankova T, Mitha I . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2008; 32(1):84-90. PMC: 2606836. DOI: 10.2337/dc08-1355. View

18.

Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic N, Antic S . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-55. PMC: 2744824. DOI: 10.1007/s00125-009-1472-y. View

19.

Brodovicz K, Kou T, Alexander C, ONeill E, Engel S, Girman C . Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012; 14(12):1123-8. DOI: 10.1111/j.1463-1326.2012.01667.x. View

20.

Perry C . Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2011; 71(17):2347-73. DOI: 10.2165/11208110-000000000-00000. View